Close
Almac
Achema middle east

Drug Development: Making the impossible possible

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

Building Resilient Pharma Portfolios in an Era of Scientific and Market Uncertainty

Pharmaceutical companies are radically redesigning portfolio strategies to survive a "triple threat" environment of scientific complexity, regulatory upheaval like the IRA, and capital scarcity. This analysis explores the shift from efficiency-driven models to resilience-first frameworks, detailing how leaders are embedding optionality into pipelines, embracing modality agnosticism, and using dynamic resource allocation to thrive amidst volatility.

AI-Crafted Pill Succeeds Trials of Plaque Psoriasis Patients

Takeda Pharmaceutical from Japan said on December 17, 2025,...

Largest Vaccine Manufacturing Facility in Egypt Launched

Egypt has gone on to mark quite a prominent...
- Advertisement -

THE Advancing Drug Development Forum has confirmed a prestigious line-up of leading industry voices to speak at its inaugural event.

Taking place on November 30, 2017 in Boston, USA, the forum will see pharmaceutical experts and scientists from across the globe come together to exchange ideas and experiences and conduct a deep dive into the real-world challenges of drug development in the biotech and pharma sectors.

The speakers and panellists will explore new solutions, promising technology breakthroughs and how the industry can introduce improved approaches during drug development.

The impressive line-up includes an opening keynote: ‘Minimizing CMC Risk to Maximize Probability of Success’ from Anthony A. McKinney; founder, president & CEO of Ethismos and founder and chief development officer of Neurovance, Inc.

Don Dickison, vice president, business development at event sponsor Juniper Pharma Services, said: “The forum will explore how consultants, CROs and CMOs must invest in their resources to meet the evolving demands of drug development.

“This includes informed discussion around some of the sector’s current hot topics including overcoming regulatory barriers, bringing innovative technologies and new approaches to the ‘CDMO world’ and the challenges of novel drug delivery.”

A distinguished panel of specialists that includes representatives from TetraScience, Covaris and Pion Inc. will discuss ‘Implementing the Impossible.’ Dickison added: “This is an exciting and innovative event and one which Juniper Pharma Services is proud to be part of. The caliber of the speakers and experts in attendance is second-to-none so will no doubt generate valuable discussion and learning for everyone involved.”

Manuel Sanchez-Felix, Ph.D., senior fellow, Novel Delivery Technologies, Novartis Institute for Biomedical Research and Padma Narayan, Ph.D., director, Formulation Development, Tech Ops Development, SAGE Therapeutics will also present on the day.

The closing keynote comes from Ibis Sánchez-Serrano, MBA, president & CEO of “The Core Model Corporation” (C.M.C.) and Calestous Juma, professor of the Practice of International Development, and director of the Science, Technology, and Globalization Project at the Belfer Center for Science and International Affairs of the Harvard Kennedy School who will discuss: ‘Breaking Down Barriers to Adoption of New Technology’.

Latest stories

Related stories

Building Resilient Pharma Portfolios in an Era of Scientific and Market Uncertainty

Pharmaceutical companies are radically redesigning portfolio strategies to survive a "triple threat" environment of scientific complexity, regulatory upheaval like the IRA, and capital scarcity. This analysis explores the shift from efficiency-driven models to resilience-first frameworks, detailing how leaders are embedding optionality into pipelines, embracing modality agnosticism, and using dynamic resource allocation to thrive amidst volatility.

AI-Crafted Pill Succeeds Trials of Plaque Psoriasis Patients

Takeda Pharmaceutical from Japan said on December 17, 2025,...

Largest Vaccine Manufacturing Facility in Egypt Launched

Egypt has gone on to mark quite a prominent...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »